--- title: "NeuroSense Therapeutics (NRSN) stock and investor profile" url: "https://aibio.space/companies/neurosense-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), Israel. The directory classifies it as Pharmaceuticals: Major." --- NRSN NeuroSense Therapeutics Ltd. NASDAQ · Israel # NeuroSense Therapeutics (NRSN) news Top story · Oct 2, 2026 · Company press release ## [NeuroSense Provides Update on Nasdaq Listing Compliance](https://www.sec.gov/Archives/edgar/data/1875091/000121390026106388/ea030750101ex99-1.htm) Company regains compliance with Nasdaq’s minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement Source: [6-K filed Oct 2, 2026 on SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1875091/000121390026106388/ea0307501-6k_neurosense.htm) ## Latest NeuroSense Therapeutics news We have not published a story on NeuroSense Therapeutics yet. When there is news, it will appear here. ## NeuroSense Therapeutics at a glance - **Ticker**: NRSN - **Listing**: NASDAQ - **Country**: Israel - **Cash, Dec 31, 2025**: $166,000 ### Related companies - [BioLineRX](https://aibio.space/companies/biolinerx/) TASE: BLRX - [Eocene](https://aibio.space/companies/eocene/) NASDAQ: EOCN - [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) AMEX: NSRX - [Silexion Therapeutics](https://aibio.space/companies/silexion-therapeutics/) NASDAQ: SLXN - [MediWound](https://aibio.space/companies/mediwound/) NASDAQ: MDWD - [Purple Biotech](https://aibio.space/companies/purple-biotech/) TASE: PPBT - [SciSparc](https://aibio.space/companies/scisparc/) NASDAQ: SPRC - [Sol-Gel Technologies](https://aibio.space/companies/sol-gel-technologies/) NASDAQ: SLGL ### Also on NASDAQ - [Axsome Therapeutics](https://aibio.space/companies/axsome-therapeutics/) AXSM - [Generate Biomedicines](https://aibio.space/companies/generate-biomedicines/) GENB - [Citius Pharmaceuticals](https://aibio.space/companies/citius-pharmaceuticals/) CTXR - [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) MPLT - [VERACYTE, INC.](https://aibio.space/companies/veracyte/) VCYT - [Alphatec Holdings](https://aibio.space/companies/alphatec/) ATEC ## NeuroSense Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$6.2 million](https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/) | [$5.7 million](https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/) | | Net income (loss) | [-$11.1 million](https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/) | [-$10.2 million](https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/) | | Cash from operations | [-$7.7 million](https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/) | [-$10.1 million](https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/) | | Cash and equivalents | [$166,000](https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/) | [$3.4 million](https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $166,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NeuroSense Therapeutics What is the ticker symbol of NeuroSense Therapeutics? NeuroSense Therapeutics Ltd. trades under the ticker NRSN on NASDAQ. Where is NeuroSense Therapeutics listed? NeuroSense Therapeutics Ltd. is listed on NASDAQ. What is the SEC CIK of NeuroSense Therapeutics? The SEC Central Index Key (CIK) for NeuroSense Therapeutics Ltd. is 1875091. Its filings are on SEC EDGAR. How many shares does NeuroSense Therapeutics have outstanding? 32,557,174 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-31. Which country or territory is NeuroSense Therapeutics listed under? Our directory records NeuroSense Therapeutics Ltd. under Israel. What does NeuroSense Therapeutics do? Our directory classifies NeuroSense Therapeutics Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of NeuroSense Therapeutics? The ISIN recorded for NeuroSense Therapeutics Ltd. is IL0011809592. Does aibio.space cover NeuroSense Therapeutics? aibio.space lists NeuroSense Therapeutics Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is NeuroSense Therapeutics incorporated? SEC records list its state or country of incorporation as L3. Is NeuroSense Therapeutics profitable? NeuroSense Therapeutics Ltd. reported a net loss of $11.1 million for the fiscal year ended Dec 31, 2025, and used $7.7 million of cash in operations, per its annual report to the SEC. How much does NeuroSense Therapeutics spend on research and development? $6.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does NeuroSense Therapeutics have? $166,000 in cash at Dec 31, 2025, per its 20-F. Is NeuroSense Therapeutics a smaller reporting company? SEC records list NeuroSense Therapeutics Ltd.'s filer category as: Non-accelerated filer
Emerging growth company. Where is NeuroSense Therapeutics headquartered? SEC records list its business address as 11 HAMENOFIM ST., HERZLIYA, Israel, 4672562. When does NeuroSense Therapeutics's fiscal year end? NeuroSense Therapeutics Ltd.'s fiscal year ends on December 31, per SEC records. ## Investor discussion: NeuroSense Therapeutics Members talk about NeuroSense Therapeutics (NRSN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NeuroSense Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026108759/ea030843601ex99-1.htm) 2. 2026-10-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026106388/ea030750101ex99-1.htm) 3. 2026-09-25 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026103534/ea030656401ex99-1.htm) 4. 2026-09-09 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026098414/ea0304823-6k_neurosense.htm) 5. 2026-08-27 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026094389/ea0303658-6k_neurosense.htm) 6. 2026-08-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026088851/ea030197401ex99-1.htm) 7. 2026-07-31 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026083987/ea029982101ex99-1.htm) 8. 2026-04-28 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026048513/ea028810301ex99-1.htm) 9. 2026-04-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026039734/ea028505901ex99-1.htm) 10. 2026-01-29 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390026009643/ea0274510-f3_neurosense.htm) 11. 2025-08-01 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390025070315/ea025084301ex99-1_neurosense.htm) 12. 2025-01-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390025000994/ea022687201ex99-1_neuro.htm) 13. 2024-12-26 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390024112695/ea0226024-f3_neurosense.htm) 14. 2024-12-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390024109699/ea0225129-6k_neuro.htm) 15. 2024-12-02 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390024104568/ea022334001ex99-1_neurosense.htm) 16. 2024-11-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1875091/000121390024096273/ea0220815-6k_neurosense.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NRSN on TradingView](https://www.tradingview.com/symbols/NASDAQ-NRSN/). ## SEC filings and registration - **SEC name**: NeuroSense Therapeutics Ltd. - **CIK**: 1875091 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NRSN (Nasdaq), NRSNW (Nasdaq) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: 11 HAMENOFIM ST., HERZLIYA, Israel, 4672562 - **Phone**: 972-9-9531142 - **Shares outstanding**: 32,557,174 as of 2025-12-31 (20-F filed 2026-03-31) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390026110516/ea0308988-6k_neurosense.htm) filed 2026-10-19 - [6-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390026108759/ea0308436-6k_neurosense.htm) filed 2026-10-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390026106388/ea0307501-6k_neurosense.htm) filed 2026-10-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390026103534/ea0306564-6k_neurosense.htm) filed 2026-09-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390026098414/ea0304823-6k_neurosense.htm) filed 2026-09-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390026094389/ea0303658-6k_neurosense.htm) filed 2026-08-27 - [6-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390026088851/ea0301974-6k_neuro.htm) filed 2026-08-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390026086007/ea0300915-6k_neuro.htm) filed 2026-08-06 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001875091), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NeuroSense Therapeutics Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NRSN, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NeuroSense Therapeutics Ltd. - **Ticker**: NRSN - **Listing**: NASDAQ - **Country or territory**: Israel - **Business scope**: Pharmaceuticals: Major - **ISIN**: IL0011809592 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NRSN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/neurosense-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NeuroSense Therapeutics (NRSN) stock and investor profile", 2026-10-31, https://aibio.space/companies/neurosense-therapeutics/